OncLive TV

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer. 

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

Glenn J. Hanna, MD, discusses the role of second-line cetuximab (Erbitux) in head and neck cancer.

Anthony Mato, MD, MSCE, discusses recent advances made in the treatment of patients with chronic lymphocytic leukemia.

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.

Francine Foss, MD, discusses pursing new therapeutic options for the treatment of patients with T-cell non-Hodgkin lymphoma.

Maher Albitar, MD, discusses the importance of obtaining genomic testing in oncology.

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

Paul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

Phillip Palmbos, MD, PhD, discusses updates and therapeutic recommendations for the frontline treatment of patients with bladder cancer.

Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer. 

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer. 

Edgardo S. Santos, MD, FACP, discusses the importance of identifying mechanisms of resistance in lung cancer.

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.